NTLA Intellia Therapeutics Inc

Price (delayed)

$129.6

Market cap

$9.52B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.87

Enterprise value

$9.46B

Intellia Therapeutics is a biotechnology company developing biopharmaceuticals using a CRISPR gene editing system invented by Jennifer Doudna and Virginijus Šikšnys . The company has partnerships with Novartis and Regeneron. ...

Highlights
The company's debt fell by 2.8% QoQ
Intellia Therapeutics's equity has increased by 41% YoY but it has decreased by 9% from the previous quarter
The net income has plunged by 59% YoY and by 24% from the previous quarter
The company's quick ratio fell by 26% QoQ and by 3.6% YoY

Key stats

What are the main financial stats of NTLA
Market
Shares outstanding
73.49M
Market cap
$9.52B
Enterprise value
$9.46B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
17.85
Price to sales (P/S)
211.29
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
226.37
Earnings
Revenue
$41.81M
EBIT
-$185.04M
EBITDA
-$178.61M
Free cash flow
-$181.2M
Per share
EPS
-$2.87
Free cash flow per share
-$2.66
Book value per share
$7.26
Revenue per share
$0.61
TBVPS
$9.86
Balance sheet
Total assets
$672.24M
Total liabilities
$177.43M
Debt
$70.67M
Equity
$494.81M
Working capital
$475.44M
Liquidity
Debt to equity
0.14
Current ratio
7.43
Quick ratio
7.18
Net debt/EBITDA
0.33
Margins
EBITDA margin
-427.2%
Gross margin
100%
Net margin
-442.6%
Operating margin
-444.7%
Efficiency
Return on assets
-29.3%
Return on equity
-39%
Return on invested capital
-39.7%
Return on capital employed
-30.9%
Return on sales
-442.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

NTLA stock price

How has the Intellia Therapeutics stock price performed over time
Intraday
-1.82%
1 week
0.36%
1 month
-12.18%
1 year
409.43%
YTD
138.24%
QTD
-3.39%

Financial performance

How have Intellia Therapeutics's revenue and profit performed over time
Revenue
$41.81M
Gross profit
$41.81M
Operating income
-$185.94M
Net income
-$185.04M
Gross margin
100%
Net margin
-442.6%
The company's net margin has shrunk by 93% YoY and by 53% QoQ
Intellia Therapeutics's operating margin has shrunk by 86% YoY and by 53% QoQ
The net income has plunged by 59% YoY and by 24% from the previous quarter
The company's operating income has shrunk by 53% YoY and by 24% QoQ

Growth

What is Intellia Therapeutics's growth rate over time

Valuation

What is Intellia Therapeutics stock price valuation
P/E
N/A
P/B
17.85
P/S
211.29
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
226.37
The EPS has contracted by 24% YoY and by 16% from the previous quarter
The stock's P/B is 70% above its last 4 quarters average of 10.5
Intellia Therapeutics's equity has increased by 41% YoY but it has decreased by 9% from the previous quarter
The price to sales (P/S) is 92% higher than the last 4 quarters average of 110.0
Intellia Therapeutics's revenue has decreased by 19% QoQ and by 18% YoY

Efficiency

How efficient is Intellia Therapeutics business performance
The ROS has plunged by 93% YoY and by 53% from the previous quarter
Intellia Therapeutics's ROIC has increased by 26% YoY and by 5% from the previous quarter
The ROA has contracted by 15% from the previous quarter but it has grown by 6% YoY
Intellia Therapeutics's ROE has decreased by 15% from the previous quarter but it has increased by 3.9% YoY

Dividends

What is NTLA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NTLA.

Financial health

How did Intellia Therapeutics financials performed over time
The total assets has grown by 37% YoY but it has contracted by 6% from the previous quarter
Intellia Therapeutics's total liabilities has increased by 27% YoY and by 3.7% QoQ
The company's debt is 86% lower than its equity
The debt to equity has soared by 100% YoY and by 8% from the previous quarter
Intellia Therapeutics's equity has increased by 41% YoY but it has decreased by 9% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.